"Stocks seem so difficult with so much to study..." "Don't you have to be able to read world affairs and financial statements ...

Royalty Pharma invests in a portfolio of drugs, from blockbusters to those still in development.

JELMYTO provides growing but limited revenue for Urogen. Urogen's best shot at success for its shareholders depends on its UGN-102. Urogen has adequate financial resources to carry it to submission of ...